RxDoctor Payments Data

Lori Gerding, MD

Psychiatry · Moncks Corner, SCNPI 1801834726

Payments from drug & device makers

$5,315in general payments, 2019–2025

Across 364 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Neurocrine Biosciences, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$893
  • Supernus Pharmaceuticals, Inc.$451
  • Otsuka America Pharmaceutical, Inc.$375
  • Alkermes, Inc.$309
  • plus $966 from 13 others

What the payments were for

  • Food & beverage$5,315100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,315 in reported general payments places this provider in the 85th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$39,668
Medicare patients
103
Services billed
543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine35$267,009
Abilify MaintenaAripiprazole33$96,074
Invega SustennaPaliperidone Palmitate26$92,370
Aripiprazole57$10,008
Clozapine28$2,610
Hydroxyzine Hcl55$1,931
Ziprasidone Hcl17$1,006
Benztropine Mesylate54$677
Trazodone Hcl56$592
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$578
Divalproex Sodium19$575
Duloxetine Hcl51$489
Quetiapine Fumarate23$469
Gabapentin29$439
Prazosin Hcl28$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$893$267,00935 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$375$96,07433 claims
Johnson & JohnsonInvega Sustenna$1,316$92,37026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Moncks Corner

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →